Letter to the Editor: Autoantibody profiling in gastric cancer immunotherapy - dynamic monitoring, toxicity-benefit trade-off, and immune endotypes

doi:10.3748/wjg.120350

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 36

This Article

(0)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article (XML)

Correspondence

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Sep 28, 2026; 32(36): 120350
Published online Sep 28, 2026. doi: 10.3748/wjg.120350

Letter to the Editor: Autoantibody profiling in gastric cancer immunotherapy - dynamic monitoring, toxicity-benefit trade-off, and immune endotypes

Wan-Ting Huang, Bin-Bin Zhang, Jia-Nan Zhao

Wan-Ting Huang, School of Public Health and Nursing, Hangzhou Normal University, Hangzhou 311121, Zhejiang Province, China

Bin-Bin Zhang, School of Clinical Medicine, Hangzhou Normal University, Hangzhou 311121, Zhejiang Province, China

Jia-Nan Zhao, Department of Cardiovascular Sciences, Temple University, Philadelphia, PA 19140, United States

Co-corresponding authors: Bin-Bin Zhang and Jia-Nan Zhao.

Author contributions: Huang WT performed the literature retrieval and evidence synthesis, organized the references, and drafted the original manuscript; Zhang BB and Zhao JN conceptualized and designed the study framework, defined the academic positioning and core perspectives, provided substantial intellectual input, critically revised the manuscript for key scientific content, and supervised the entire work; they contributed equally to this article, they are the co-corresponding authors of this manuscript; and all authors reviewed and approved the final submitted version.

Supported by National Natural Science Foundation of China, No. 82204827.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Corresponding author: Jia-Nan Zhao, Academic Fellow, Department of Cardiovascular Sciences, Temple University, North Carlisle Street, 3440 Carlisle st, Philadelphia, PA 19140, United States. tuv36393@temple.edu

Received: February 24, 2026
Revised: April 4, 2026
Accepted: May 12, 2026
Published online: September 28, 2026
Processing time: 178 Days and 15.6 Hours

Core Tip

Core Tip: Baseline antinuclear antibody/extractable nuclear antigen status may serve as a potential predictor of immunotherapy outcomes in gastric cancer. However, static indicators fail to capture dynamic autoantibody changes or the underlying differences in immune endotypes. We propose to build a composite host-tumor model that integrates longitudinal antibody profiles, detailed staining patterns, and safety data, and apply calibration curves and decision curve analysis to evaluate its net clinical benefit, thereby promoting the establishment of more refined risk stratification strategies and facilitating the practice of personalized immuno-oncology.